[144] Roivant Sciences Ltd. SEC Filing

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) insider notice under Rule 144: This Form 144 reports a proposed sale of 100,000 common shares by a person for whose account the securities are to be sold, using Rockefeller Financial LLC as broker on 09/22/2025. The filing states an aggregate market value of $1,501,338.85 for the shares and notes there are 682,881,743 shares outstanding.

The shares were acquired the same day through an options exercise (grant date 04/20/2022) from Roivant Sciences Ltd., with payment by wire. The filer also discloses two prior sales in the past three months: 100,000 shares sold on 08/20/2025 (gross proceeds $1,172,120.12) and 100,000 shares sold on 07/21/2025 (gross proceeds $1,151,941.91).

Positive

• Filing is live and compliant with Rule 144, providing required broker, share count, and acquisition details
• Source of shares disclosed as an options exercise (grant date 04/20/2022), clarifying the origin of the securities
• Recent trading history disclosed with two prior sales in July and August 2025, increasing transparency

Negative

• Insider sell activity with three 100,000-share transactions in July, August, and planned September 2025
• No additional context in the filing about rationale for sales or whether a 10b5-1 plan is in place

Insights

Securities Analyst

TL;DR: Routine insider sale notice showing option exercise and planned resale; disclosed recent month-by-month sales.

The filing documents an options exercise and immediate proposed resale of 100,000 common shares via a broker, plus two prior dispositions in July and August 2025. This is a transactional, disclosure-focused filing rather than an operational update. For investors, the key points are the source of the shares (options exercise) and the timing of serial sales which may reflect liquidity needs rather than company performance. The filing complies with Rule 144 disclosure requirements and names the executing broker and payment method.

Corporate Governance Expert

TL;DR: Form 144 properly notifies the market of proposed resale; contains representation about absence of undisclosed material information.

The notice includes the required representation that the seller is unaware of undisclosed material adverse information and identifies the acquisition method (options exercise) and payment details. The inclusion of two recent sales in the past three months provides transparency on trading activity for the account. There are no statements in the filing indicating any governance changes, compensation adjustments, or material corporate events tied to these transactions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	100000	1501338.85	682881743	09/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	09/22/2025	Options Exercise - Grant Date 4/20/2022	Roivant Sciences Ltd.			100000	09/22/2025	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common shares	08/20/2025	100000	1172120.12
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway,, London X0 SW1HODB	Common Stock	07/21/2025	100000	1151941.91

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ROIV Form 144 filed on 09/22/2025 report?

The filing reports a proposed sale of 100,000 common shares via Rockefeller Financial LLC on 09/22/2025 with an aggregate market value of $1,501,338.85.

How were the ROIV shares being sold acquired?

The 100,000 shares were acquired on 09/22/2025 through an options exercise (grant date 04/20/2022) from Roivant Sciences Ltd., with payment by wire.

Has the seller recently sold other ROIV shares?

Yes. The filing discloses prior sales of 100,000 shares on 08/20/2025 (gross proceeds $1,172,120.12) and 100,000 shares on 07/21/2025 (gross proceeds $1,151,941.91).

How many ROIV shares are outstanding according to the filing?

The filing lists 682,881,743 shares outstanding.

Who is the broker named in the Form 144?

The broker named for the proposed sale is Rockefeller Financial LLC, 45 Rockefeller Plaza, Floor 5, New York, NY.